S&P 500   3,139.96 (+0.13%)
DOW   27,930.66 (+0.08%)
QQQ   204.68 (+0.30%)
AAPL   269.65 (+1.02%)
FB   200.82 (-0.26%)
MSFT   151.88 (+0.34%)
GOOGL   1,345.58 (+0.19%)
AMZN   1,747.04 (-0.14%)
CGC   20.48 (-3.80%)
NVDA   215.34 (+1.49%)
BABA   202.24 (+1.76%)
GE   11.01 (+0.18%)
AMD   39.39 (+1.16%)
ACB   2.51 (-4.20%)
F   9.03 (+0.22%)
PRI   135.23 (-0.09%)
BAC   33.48 (-0.09%)
DIS   146.30 (+0.05%)
S&P 500   3,139.96 (+0.13%)
DOW   27,930.66 (+0.08%)
QQQ   204.68 (+0.30%)
AAPL   269.65 (+1.02%)
FB   200.82 (-0.26%)
MSFT   151.88 (+0.34%)
GOOGL   1,345.58 (+0.19%)
AMZN   1,747.04 (-0.14%)
CGC   20.48 (-3.80%)
NVDA   215.34 (+1.49%)
BABA   202.24 (+1.76%)
GE   11.01 (+0.18%)
AMD   39.39 (+1.16%)
ACB   2.51 (-4.20%)
F   9.03 (+0.22%)
PRI   135.23 (-0.09%)
BAC   33.48 (-0.09%)
DIS   146.30 (+0.05%)
S&P 500   3,139.96 (+0.13%)
DOW   27,930.66 (+0.08%)
QQQ   204.68 (+0.30%)
AAPL   269.65 (+1.02%)
FB   200.82 (-0.26%)
MSFT   151.88 (+0.34%)
GOOGL   1,345.58 (+0.19%)
AMZN   1,747.04 (-0.14%)
CGC   20.48 (-3.80%)
NVDA   215.34 (+1.49%)
BABA   202.24 (+1.76%)
GE   11.01 (+0.18%)
AMD   39.39 (+1.16%)
ACB   2.51 (-4.20%)
F   9.03 (+0.22%)
PRI   135.23 (-0.09%)
BAC   33.48 (-0.09%)
DIS   146.30 (+0.05%)
S&P 500   3,139.96 (+0.13%)
DOW   27,930.66 (+0.08%)
QQQ   204.68 (+0.30%)
AAPL   269.65 (+1.02%)
FB   200.82 (-0.26%)
MSFT   151.88 (+0.34%)
GOOGL   1,345.58 (+0.19%)
AMZN   1,747.04 (-0.14%)
CGC   20.48 (-3.80%)
NVDA   215.34 (+1.49%)
BABA   202.24 (+1.76%)
GE   11.01 (+0.18%)
AMD   39.39 (+1.16%)
ACB   2.51 (-4.20%)
F   9.03 (+0.22%)
PRI   135.23 (-0.09%)
BAC   33.48 (-0.09%)
DIS   146.30 (+0.05%)
Log in

NASDAQ:OBSV - Obseva Stock Price, Forecast & News

$3.37
+0.14 (+4.33 %)
(As of 12/10/2019 10:42 AM ET)
Today's Range
$3.35
Now: $3.37
$3.88
50-Day Range
$2.48
MA: $4.98
$7.94
52-Week Range
$2.37
Now: $3.37
$15.93
Volume3.52 million shs
Average Volume374,245 shs
Market Capitalization$153.27 million
P/E RatioN/A
Dividend YieldN/A
Beta0.59
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.23 per share

Profitability

Net Income$-76,720,000.00

Miscellaneous

Employees43
Market Cap$153.27 million
Next Earnings Date3/3/2020 (Estimated)
OptionableNot Optionable

Receive OBSV News and Ratings via Email

Sign-up to receive the latest news and ratings for OBSV and its competitors with MarketBeat's FREE daily newsletter.


Obseva (NASDAQ:OBSV) Frequently Asked Questions

What is Obseva's stock symbol?

Obseva trades on the NASDAQ under the ticker symbol "OBSV."

How were Obseva's earnings last quarter?

Obseva SA (NASDAQ:OBSV) issued its earnings results on Thursday, November, 7th. The company reported ($0.63) EPS for the quarter, beating analysts' consensus estimates of ($0.82) by $0.19. View Obseva's Earnings History.

When is Obseva's next earnings date?

Obseva is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Obseva.

What price target have analysts set for OBSV?

4 brokerages have issued 12-month price objectives for Obseva's shares. Their forecasts range from $4.00 to $38.00. On average, they expect Obseva's share price to reach $24.25 in the next twelve months. This suggests a possible upside of 600.9% from the stock's current price. View Analyst Price Targets for Obseva.

What is the consensus analysts' recommendation for Obseva?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Obseva in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Obseva.

What are Wall Street analysts saying about Obseva stock?

Here are some recent quotes from research analysts about Obseva stock:
  • 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (11/9/2019)
  • 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our risk-adjusted net present value (rNPV) approach ascribes $1.9B to linzagolix (formerly to nolasiban. We utilize an 85% probability of approval for linzagolix and 75% for nolasiban." (9/4/2019)

Has Obseva been receiving favorable news coverage?

Media coverage about OBSV stock has trended negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Obseva earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Obseva.

Who are some of Obseva's key competitors?

What other stocks do shareholders of Obseva own?

Who are Obseva's key executives?

Obseva's management team includes the folowing people:
  • Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 67)
  • Mr. Timothy M. Adams, Chief Financial Officer (Age 59)
  • Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer and Head of R&D (Age 54)
  • Mr. Mario Vincent Corso, Sr. Director of Investor Relations
  • Dr. Elke Bestel M.D., Chief Medical Officer & Head of Pharmacovigilance (Age 53)

When did Obseva IPO?

(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.

Who are Obseva's major shareholders?

Obseva's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (0.50%) and Wedbush Securities Inc. (0.09%).

Which institutional investors are selling Obseva stock?

OBSV stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P..

Which institutional investors are buying Obseva stock?

OBSV stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc..

How do I buy shares of Obseva?

Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Obseva's stock price today?

One share of OBSV stock can currently be purchased for approximately $3.46.

How big of a company is Obseva?

Obseva has a market capitalization of $157.36 million. The company earns $-76,720,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Obseva employs 43 workers across the globe.View Additional Information About Obseva.

What is Obseva's official website?

The official website for Obseva is http://www.obseva.com/.

How can I contact Obseva?

Obseva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]


MarketBeat Community Rating for Obseva (NASDAQ OBSV)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  243 (Vote Outperform)
Underperform Votes:  254 (Vote Underperform)
Total Votes:  497
MarketBeat's community ratings are surveys of what our community members think about Obseva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel